达安基因(002030) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥588,829,623.53, representing a 133.16% increase compared to ¥252,539,215.94 in the same period last year[8] - Net profit attributable to shareholders for Q1 2020 reached ¥186,368,214.09, a significant increase of 559.37% from ¥28,264,522.13 in the previous year[8] - Basic earnings per share for Q1 2020 were ¥0.2337, up 560.17% from ¥0.0354 in the same period last year[8] - The company's net profit for the first half of 2020 is expected to rise by over 50%, with a projected range of RMB 30,256.60 million to RMB 45,000.00 million, compared to RMB 6,051.32 million in the same period of 2019[33] - The company's net profit for the current period was ¥183,534,807.04, compared to ¥28,899,197.39 in the previous period, indicating a substantial increase of about 535.5%[78] - The total profit for the current period was ¥218,586,973.29, up from ¥36,988,102.13 in the previous period, representing an increase of about 489.0%[78] Cash Flow - The net cash flow from operating activities was ¥210,054,658.97, showing a remarkable increase of 2,099.86% compared to ¥9,548,557.09 in the same period last year[8] - The cash flow from operating activities for the current period was ¥442,596,531.00, significantly higher than ¥230,203,010.37 in the previous period, reflecting an increase of approximately 92.1%[88] - Cash inflow from operating activities totaled 489,125,823.24, while cash outflow was 279,071,164.27, resulting in a net cash inflow of 210,054,658.97[91] - The company reported a net cash outflow from investing activities of -5,925,583.22, an improvement from -19,429,545.43 in the previous period, reflecting better investment management[94] - The ending cash and cash equivalents balance increased to 363,664,094.48, compared to 273,543,761.18 in the previous period, showing improved liquidity[97] Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥3,845,233,244.37, an increase of 7.96% from ¥3,561,622,714.71 at the end of the previous year[8] - The company's current assets reached CNY 2,033,830,115.70, up from CNY 1,751,548,560.79, indicating an increase of about 16.09%[54] - Total liabilities increased to CNY 1,574,216,861.47 from CNY 1,474,123,760.72, representing a rise of approximately 6.78%[60] - The company's equity attributable to shareholders rose to CNY 2,027,862,720.15 from CNY 1,841,511,884.19, an increase of about 10.1%[60] - Total liabilities amounted to ¥982,925,768.66, an increase from ¥904,825,319.00, reflecting a rise of approximately 8.6%[70] Shareholder Information - The total number of shareholders at the end of the reporting period was 116,200, with the top ten shareholders holding significant stakes[18] - Guangzhou Zhongda Holdings Co., Ltd. is the largest shareholder, holding 16.63% of the shares[18] Research and Development - Research and development expenses rose by 54.10% to RMB 28,060,251.38 from RMB 18,209,387.87, indicating increased investment in R&D[29] - Research and development expenses increased to ¥28,060,251.38 from ¥18,209,387.87, representing a growth of about 54.1%[73] - Research and development expenses for the current period amounted to ¥15,512,081.46, which is an increase from ¥8,511,186.12 in the previous period, showing a growth of approximately 82.5%[82] Government Subsidies - The company received government subsidies amounting to ¥7,587,271.72 during the reporting period[10] Other Financial Metrics - The weighted average return on equity for Q1 2020 was 9.63%, compared to 1.54% in the same period last year, reflecting an increase of 8.09%[8] - The company's financial expenses decreased to ¥6,516,410.59 from ¥10,031,685.13 in the previous period, a reduction of about 35.1%[82] - The company's deferred income decreased by 42.25% to RMB 8,915,119.84 from RMB 15,436,967.84, as deferred income was recognized in the current period[29] - The company reported a decrease in other comprehensive income, with a net amount of ¥0.00 for the current period compared to a loss of ¥725,098.19 in the previous period[80]